These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36856762)
1. Cystic fibrosis liver disease in children - A review of our current understanding. Costaguta G; Patey N; Álvarez F Arch Argent Pediatr; 2023 Aug; 121(4):e202202905. PubMed ID: 36856762 [TBL] [Abstract][Full Text] [Related]
2. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)]. ; ; Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700 [TBL] [Abstract][Full Text] [Related]
6. Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients. Mallea J; Bolan C; Cortese C; Harnois D Liver Transpl; 2019 Aug; 25(8):1265-1275. PubMed ID: 31102574 [TBL] [Abstract][Full Text] [Related]
7. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Palaniappan SK; Than NN; Thein AW; van Mourik I Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012056. PubMed ID: 32227478 [TBL] [Abstract][Full Text] [Related]
8. Assessment of liver disease in cystic fibrosis. Davison S Paediatr Respir Rev; 2018 Jun; 27():24-27. PubMed ID: 29933897 [TBL] [Abstract][Full Text] [Related]
9. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Derichs N Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166 [TBL] [Abstract][Full Text] [Related]
10. Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators. Colombo C; Ramm GA; Lindblad A; Corti F; Porcaro L; Alghisi F; Asherova I; Evans H; Kashirskaya N; Kondratyeva E; Lewindon PJ; de Monestrol I; Oliver M; Ooi CY; Padoan R; Shankar S; Alicandro G J Cyst Fibros; 2023 Mar; 22(2):263-265. PubMed ID: 36739240 [TBL] [Abstract][Full Text] [Related]
11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
12. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis. Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799 [TBL] [Abstract][Full Text] [Related]
13. Unusual Cystic Fibrosis Transmembrane Conductance Regulator Mutations and Liver Disease: A Case Series and Review of the Literature. Khan HH; Mew NA; Kaufman SS; Yazigi NA; Fishbein TM; Khan KM Transplant Proc; 2019 Apr; 51(3):790-793. PubMed ID: 30979466 [TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Fiorotto R; Strazzabosco M Cell Mol Gastroenterol Hepatol; 2019; 8(2):197-207. PubMed ID: 31075352 [TBL] [Abstract][Full Text] [Related]
18. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
19. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426 [TBL] [Abstract][Full Text] [Related]
20. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Durie PR; Kent G; Phillips MJ; Ackerley CA Am J Pathol; 2004 Apr; 164(4):1481-93. PubMed ID: 15039235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]